Synchronized Cardiac Support with the icor kit: Patients with cardiogenic shock, requiring a venoarterial extracorporeal membrane oxygenation (VA ECMO) for cardiocirculatory stabilization will be treated with Synchronized Cardiac Support (SCS).
Study summary
The study aims to investigate the safety and efficacy of the Synchronized Cardiac Support treatment wit the icor kit and the Xenios console with modified sensor box ECG and Software Version 3.2.4
Eligibility
Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria:
1. Informed consent signed and dated by study patient/legal representative and investigator/authorised physician
2. Minimum age of 18 years
3. Patients in cardiogenic shock
4. Cardiogenic shock is defined as:
1. Systolic blood pressure \< 90 mmHg for at least 30 min
2. Inotropes and/or vasopressors are needed to maintain systolic blood pressure \> 90 mmHg
3. Clinical signs of heart insufficiency with pulmonary congestion
5. Signs of end organ hypoperfusion with at least one of the following criteria:
1. Cold, damp skin or extremities
2. Oliguria (≤ 30 mL/h)
6. Serum lactate \> 3.0 mmol/L
Exclusion Criteria:
1. In case of female patients: pregnancy or lactation period
2. Participation in an interventional clinical study during the preceding 30 days
3. Previous participation in the same study
4. Age \> 85 years
5. Cardiac arrest out of hospital with return of spontaneous circulation (ROSC) \> 30 min
6. No flow time \> 5 min
7. Mechanical causes for cardiogenic shock (ventricular septal defect of papillary muscle rupture)
8. Non-cardiogenic causes of shock (bradycardia, sepsis, hypovolemia, etc.)
9. Fever (Body temperature \> 38.0 °C) or other evidence of sepsis
10. Onset of cardiogenic shock \> 6 h before enrolment
11. Lactate \> 16 mmol/L
12. Severe peripheral arterial occlusive disease precluding insertion of femoral arterial or venous catheters
13. Contra-indications for anticoagulation
14. Contra-indication for VA ECMO, e.g. unrecoverable heart and not a candidate for transplant or VAD
Primary outcome measure(s)
Cardiocirculatory stabilization and end-organ perfusion — up to 14 days measured by the Change in Lactate Level
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.